Cannabidivarin - GW Pharmaceuticals

Drug Profile

Cannabidivarin - GW Pharmaceuticals

Alternative Names: CBDV - GW Pharmaceuticals; GWP-42006

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Charite - Universitatsmedizin Berlin; GW Pharmaceuticals
  • Class Antiepileptic drugs; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Partial epilepsies
  • Phase I Epilepsy; Pervasive child development disorders

Most Recent Events

  • 07 Aug 2017 GW Pharmaceuticals announces full enrolment of a phase II partial-onset epilepsy study in adults
  • 07 Aug 2017 GW Pharmaceuticals plans a placebo-controlled clinical trial for Rett syndrome in the first half of 2018
  • 07 Aug 2017 GW Pharmaceuticals plans an open-label clinical trial for Rett syndrome in the fourth half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top